CIK 0001517022 · Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208756903
- Phone
- 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- 4 Open-market sale SVP, CFO & Treasurer sold 6,976 shares at $8.70 ($60,691)
- 4 Open-market sale SVP, Chief Development Officer sold 3,454 shares at $8.70 ($30,050)
- 4 Grant or award CEO and President acquired 237,400 shares (grant or award)
- 4 Grant or award SVP, Chief Medical Officer acquired 62,000 shares (grant or award)
- 4 Grant or award CCO acquired 55,000 shares (grant or award)
- SEC STAFF LETTER Other SEC Staff Letter Redacted Exhibit
- 8-K Event Other events
- 5 Insider Annual Insider Trading Report
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- SEC STAFF LETTER Other SEC Staff Letter Redacted Exhibit
- CT ORDER Other Confidential Order
- SC 13G/A Stake Amended Statement of Ownership
- S-8 Other Securities Offered to Employees in Benefit Plans
- 4 Open-market buy Director bought 5,800 shares at $3.43 ($19,894)
- 4 Open-market buy Director bought 15,000 shares at $3.52 ($52,800)
- 4 Open-market buy SVP, Chief Medical Officer bought 27,000 shares at $3.58 ($96,660)
- 4 Open-market buy CEO and President bought 50,000 shares at $3.44 ($172,000)
- 4 Open-market buy Director bought 50,000 shares at $3.41 ($170,500)
- UPLOAD Other SEC-generated Letter
Page 23 of 45 · 886 filings